Past Episodes

An exercise program can be hard to start and even more difficult to stick with. But the evidence-based benefits speak for themselves. For people living with MS, it can mean improving quality of life without having to rely on a pill, injection, or infusion. And exercise is 100% affordable! Dr. Robert Motl, the Director of the Exercise Neuroscience Research Laboratory at the College of Applied Health Sciences at the University of Illinois Chicago, joins me to discuss how exercise can improve MS-r...

When you join the iConquer MS community, you're no longer just a patient; you become a research partner. Not just a data point in someone's study. You become the person to suggest the study, to help define the study, and to participate in sharing the outcome of the study. In this week's episode, I talk with the iConquer MS leadership team about what it means to be part of this people-powered research revolution and how iConquer MS keeps people affected by MS at the center of MS research. The Na...

Last week, about 170 MS activists from across the country gathered in Washington, D.C. to participate in the National MS Society's Public Policy Conference. It's hard to come away from this event and not feel outraged by the stories that are shared, but also inspired by the resilience and bravery of the MS Activists who are willing to share some of the worst moments in their MS journey to make sure that our elected representatives in the House and Senate understand why the legislation we ask the...

In 1988, there were just 42 Walk MS events, raising approximately $4 million. In 2025, there were 170 events across the country that raised over $30 million. As the largest private funder of MS research in the world, the National MS Society relies on funds raised at events like Walk MS to continue supporting the work that brings us closer to cures. This week, Brigitte Delaney, an amazing fundraiser and captain of the Many Sisters Walk MS team, shares her story, talks about the origin of the Man...

175 MS activists are heading to Washington, D.C. next week for the National MS Society's Public Policy Conference. Their mission: to bring the concerns of the MS community directly to lawmakers on Capitol Hill. When it comes to the legislative support for healthcare and medical research, it's no secret that these are unusual times. Joining me to brief us on the National MS Society's ongoing advocacy efforts and give us a sneak peek at the specific legislative issues we'll be taking to Capitol H...

It's MS Awareness Week, and this year we're diving into a theme that hits home for millions: Unseen MS. Multiple sclerosis is a master of disguise; it can be entirely invisible to the naked eye while remaining profoundly life-altering for the person living it. In this episode, we're exploring the spectrum of the MS experience through two distinct, yet deeply connected stories. First, you'll hear from RealTalk MS team member Kristine Werner Ozug. Kristine shares what it's like to navigate a worl...

You know them by their trade names such as Ozempic, Wegovy, Mounjaro, and Zepbound. This class of medications is known as GLP-1 receptor agonists. And while they are best known for managing diabetes and promoting weight loss, researchers are finding that these drugs are also effective in a broad range of other health conditions. So, what about MS? My guest this week is Dr. Ellen Mowry, the principal investigator of a clinical trial to determine whether a GLP-1 drug can reduce brain inflammation...

Welcome back to the third and final part of our coverage of the 2026 ACTRIMS Forum. This week's episode bridges the gap between groundbreaking clinical research and the nuanced reality of living with MS every day. First, we'll dive into the "before" and "after" of a diagnosis, starting with Dr. Helen Tremlett's insights into the MS prodrome—those subtle, early signs that appear years before typical MS symptoms. We'll also talk with Dr. Tremlett about how other health conditions can predict long...

Welcome back to Part Two of our coverage of the 2026 ACTRIMS Forum. This week, we shift our focus to emerging therapies and clinical insights that are re-shaping the future of MS care. From the latest information on stem cell transplantation to evolving treatment strategies to the labels used to describe MS, we're breaking down the complex science into the conversations that matter most to the MS community. Joining me to discuss one of the most significant presentations from the 2026 ACTRIMS Fo...

Last week, over 1,400 scientists and clinicians gathered in San Diego, California, at the 2026 Americas Committee for Treatment and Research in Multiple Sclerosis annual meeting, better known as the ACTRIMS Forum. This week, in Part One of our coverage, you'll hear from three of the experts who presented their research at the ACTRIMS Forum. Dr. Manuel Friese, a clinician-scientist at the Institute of Neuroimmunology and Multiple Sclerosis at the University Medical Center Hamburg-Eppendorf in Ha...